Evidence map›Paper›PMID 25391026›Full record

ArticlePloS one2014

A two-step strategy to enhance activity of low potency peptides.

Jamie R Doyle, Benjamin N Harwood, Subrahmanian Tarakkad Krishnaji, Vijay M Krishnamurthy, Wei-En Lin, Jean-Philippe Fortin, Krishna Kumar, Alan S Kopin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Position of lipidation influences anticancer activity of Smac analogs.Bioorganic & medicinal chemistry letters · 2019
    Article
  2. Small cyclic agonists of iron regulatory hormone hepcidin.Bioorganic & medicinal chemistry letters · 2015
    Article
  3. Lipid-conjugated Smac analogues.Bioorganic & medicinal chemistry letters · 2015
    Article
  4. Small lipidated anti-obesity compounds derived from neuromedin U.European journal of medicinal chemistry · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jamie R DoyleTufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America.
Benjamin N HarwoodTufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America; Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, United States of America.
Subrahmanian Tarakkad KrishnajiTufts University, Department of Chemistry, Medford, Massachusetts, United States of America.
Vijay M KrishnamurthyTufts University, Department of Chemistry, Medford, Massachusetts, United States of America.
Wei-En LinTufts University, Department of Chemistry, Medford, Massachusetts, United States of America.
Jean-Philippe FortinTufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America.
Krishna KumarTufts University, Department of Chemistry, Medford, Massachusetts, United States of America.
Alan S KopinTufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America; Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, United States of America.
Tufts University · USTufts Medical Center · US

Funding

Training Program in Cardiovascular ResearchT32HL069770 · NHLBI · TUFTS MEDICAL CENTER · PI KARAS, RICHARD H · 2003 to 2013
$4.7M
Protein Design Using Unnatural Amino AcidsR01GM065500 · NIGMS · TUFTS UNIVERSITY MEDFORD · PI KUMAR, KRISHNA · 2002 to 2010
$2.5M
Synapse Neurobiology Training ProgramT32NS061764 · NINDS · TUFTS UNIVERSITY BOSTON · PI BIEDERER, THOMAS · 2009 to 2019
$1.7M
NHLBI NIH HHS T32 HL069770NHLBI NIH HHS T32-HL069770NIGMS NIH HHS R01 GM065500NIGMS NIH HHS R01-GM65500NINDS NIH HHS T32 NS061764NINDS NIH HHS T32-NS061764
6 · The paper itself

Abstract

Novel strategies are needed to expedite the generation and optimization of peptide probes targeting G protein-coupled receptors (GPCRs). We have previously shown that membrane tethered ligands (MTLs), recombinant proteins comprised of a membrane anchor, an extracellular linker, and a peptide ligand can be used to identify targeted receptor modulators. Although MTLs provide a useful tool to identify and/or modify functionally active peptides, a major limitation of this strategy is the reliance on recombinant protein expression. We now report the generation and pharmacological characterization of prototype peptide-linker-lipid conjugates, synthetic membrane anchored ligands (SMALs), which are designed as mimics of corresponding MTLs. In this study, we systematically compare the activity of selected peptides as MTLs versus SMALs. As prototypes, we focused on the precursor proteins of mature Substance P (SubP) and Cholecystokinin 4 (CCK4), specifically non-amidated SubP (SubP-COOH) and glycine extended CCK4 (CCK4-Gly-COOH). As low affinity soluble peptides these ligands each presented a challenging test case for assessment of MTL/SMAL technology. For each ligand, MTLs and corresponding SMALs showed agonist activity and comparable subtype selectivity. In addition, our results illustrate that membrane anchoring increases ligand potency. Furthermore, both MTL and SMAL induced signaling can be blocked by specific non-peptide antagonists suggesting that the anchored constructs may be orthosteric agonists. In conclusion, MTLs offer a streamlined approach for identifying low activity peptides which can be readily converted to higher potency SMALs. The ability to recapitulate MTL activity with SMALs extends the utility of anchored peptides as probes of GPCR function.

Indexed as

GlycineHEK293 CellsHumansLigandsPeptidesPiperidinesPlasmidsProtein Structure, TertiaryReceptors, G-Protein-CoupledReceptors, Neurokinin-1Recombinant ProteinsSignal TransductionSubstance PTetragastrin3-(2-methoxybenzylamino)-2-phenylpiperidineGlycineLigandsPeptidesPiperidinesReceptors, G-Protein-CoupledReceptors, Neurokinin-1Recombinant ProteinsSubstance PTetragastrin

Identifiers

PMID25391026
PMCPMC4229100
OpenAlexW2091595460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.